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http://dx.doi.org/10r the quality practice of accelerated partial breast
irradiation (APBI) as part of breast-conserving therapy for women with early-stage breast cancer.
METHODS AND MATERIALS: Members of the American Brachytherapy Society with expertise
in breast cancer and breast brachytherapy in particular devised updated guidelines for appropriate
patient evaluation and selection based on an extensive literature search and clinical experience.
RESULTS: Increasing numbers of randomized and single and multi-institution series have been
published documenting the efficacy of various APBI modalities. With more than 10-year followup,
multiple series have documented excellent clinical outcomes with interstitial APBI. Patient selec-
tion for APBI should be based on a review of clinical and pathologic factors by the clinician with
particular attention paid to age ($50 years old), tumor size (#3 cm), histology (all invasive
subtypes and ductal carcinoma in situ), surgical margins (negative), lymphovascular space invasion
(not present), and nodal status (negative). Consistent dosimetric guidelines should be used to
improve target coverage and limit potential for toxicity following treatment.
CONCLUSIONS: These guidelines have been created to provide clinicians with appropriate
patient selection criteria to allow clinicians to use APBI in a manner that will optimize clinical
outcomes and patient satisfaction. These guidelines will continue to be evaluated and revised as
future publications further stratify optimal patient selection.  2013 Published by Elsevier Inc.
on behalf of American Brachytherapy Society.Keywords: Breast cancer; Partial breast irradiation; Brachytherapy; Guidelines; Breast-conserving therapyIntroduction
Breast-conserving therapy (BCT) represents one of the
seminal treatment breakthroughs in the management of
breast cancer. With more than 20-year followup, multiple
randomized trials have found comparable outcomes
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013.
res: None.
t: None.
author. The Targeted Radiation Institute at VMOC,
s, Suite 100, Pleasanton, CA 94588. Tel.: þ1-925-
5-660-1166.
upatel@yahoo.com (R.R. Patel).
nt matter  2013 Published by Elsevier Inc. on behalf of
.1016/j.brachy.2013.02.001to preserve their breast without compromising their ability
to be cured of their cancer (1e3). Beyond simply
preserving the breast, BCT has been associated with
improved quality of life, including social functioning, body
image, and physical functioning, compared with mastec-
tomy (4). Radiation therapy (RT) represents an integral part
of BCT as multiple trials have documented increased rates
of ipsilateral breast tumor recurrence (IBTR) in women
undergoing breast-conserving surgery (BCS) without RT;
even among women considered at low risk for IBTR, RT
has been associated with a significant reduction in IBTR
(Table 1 ) with a meta-analysis confirming these findings
and identifying a breast cancer mortality benefit (1, 5e9).
One factor that often prevents women from receiving
BCS followed by adjuvant RT is the length of treatmentAmerican Brachytherapy Society.
Table 1
Breast-conserving therapy with or without RT
Trial Number of patients Trial randomization Followup (mo) Limiting factors
Local recurrence
RT (%) No RT (%)
NSABP B-06 (1) 1851 Lumpectomy  RT 248 14 39
NSABP B-21 (5) 1009 Lumpectomy þ tamoxifen  RT 87 T! 1 cm 3 16
Canadian Multi-Institutional (6) 769 Tamoxifen  RT 66 O50 y old .6 7.7
CALGB 9343 (7) 636 Tamoxifen  RT 126 O70 y old 1 7
Milan (8) 580 Quadrantectomy  RT 109 T # 2.5 cm 5.8 23.5
RT 5 radiation therapy; NSABP 5 National Surgical Adjuvant Breast and Bowel Project; CALGB 5 Cancer and Leukemia Group B; T 5 tumor size.
268 C. Shah et al. / Brachytherapy 12 (2013) 267e277required. Traditional whole-breast irradiation (WBI) typi-
cally requires 5e6 ½ weeks with studies demonstrating that
25% or more of women fail to receive adjuvant radiation
after BCS (10, 11). Accelerated partial breast irradiation
(APBI) represents a technique that allows for the delivery
of adjuvant therapy after BCS in 1 week or less with
multiple techniques available at this time to deliver APBI;
intraoperative partial breast irradiation is an another alter-
native that delivers a single fraction of RT in the perioper-
ative period. APBI allows for women who may otherwise
forgo adjuvant RT the ability to complete treatment in
an efficient manner and is increasingly being used with
a 10-fold increase noted between 2002 and 2007 (12).
With the increased use of APBI, evidence-based guide-
lines are necessary to guide clinicians with regard to
appropriate patient evaluation and selection. Although the
American Brachytherapy Society (ABS) has previously
provided guidelines for APBI, these guidelines have been
updated to reflect the significant increase in published data
and changes in clinical practice since the previous publica-
tion (13).Methods and materials
The ABS guidelines for APBI were composed by
members of the ABS with expertise in breast cancer and in
particular breast brachytherapy. The goals of this effort were
to update the previous guidelines based on a review of new
data addressing the efficacy and toxicity of APBI. Clinical
guideline development was initiated with a systematic
review of the literature with a focus on randomized trials,
multi-institution series, and single institution reports ad-
dressing clinical outcomes and toxicities. Five randomized
trials were identified along with 41 nonrandomized studies
(Phase I/II, single institution, and multi-institution).
Although randomized trials were evaluated, because of the
short followup of more recent trials, outdated or nonstandard
techniques of older trials, and a lack of power in several
trials, focus was placed on nonrandomized data when
creating the final guidelines. Current recommendations or
guidelines previously published (by other societies) were
evaluated as well. Following a discussion of the literature,
the revised guidelines were established by consensus among
the authors based on the review of the literature on the topicand their expert opinions.When evaluating the data available
and establishing guidelines, the study design and limitations
of studies were also taken into consideration. Furthermore,
guidelines were madewith the knowledge that current guide-
lines may be changed moving forward based on future pub-
lished data, in particular data from randomized trials.
Evaluation of specific guideline recommendations
With regard to age criteria for the application of APBI,
this guideline remains unchanged because of a lack of
significant new data supporting a change in the recommen-
dation. Specifically, no APBI studies were identified that
conclusively established age as risk factor for an increased
risk of IBTR when applying the technique beyond that
already identified when using BCT in general with standard
WBI.
When evaluating tumor size, the threshold was kept at
3 cm, consistent with the previous ABS guidelines and
other consensus guidelines and inclusion criteria for
randomized trials. No data were identified to suggest that
APBI should or could be applied after neoadjuvant chemo-
therapy for patients with tumors O3 cm. Similarly, when
evaluating nodal status, only node-negative patients were
included consistent with the previous ABS guidelines and
other consensus guidelines.
For surgical margins, the recommendation was based on
recently published data and confirmed with other consensus
guidelines. Specifically, very few published studies were
identified that conclusively established (or suggested) that
APBI could be applied safely in other clinical settings
(i.e., focally positive margins, etc.). The exclusion of lym-
phovascular space invasion (LVSI) was based on a combina-
tion of recently published APBI data and consensus
agreement with previously published guidelines.
For histology, a change was made to incorporate all
invasive subtypes and ductal carcinoma in situ (DCIS)
because no new data were identified establishing any other
subtype that resulted in a higher risk of IBTR. Specifically,
the inclusion of DCIS was based on a large number of new
publications supporting the clinical efficacy of APBI in
patients with DCIS. With regard to the invasive lobular
carcinomas (ILC), although there still remains limited data
regarding APBI and lobular carcinomas, the guideline was
modified to include lobular carcinomas based on (1) the
269C. Shah et al. / Brachytherapy 12 (2013) 267e277publication of two series confirming the efficacy of APBI in
this population, (2) a lack of any modern APBI study
finding increased recurrences with ILCs treated with APBI,
and (3) extrapolation from series evaluating treatment of
ILCs with standard BCT using WBI.
With regard to estrogen receptor status, there was signif-
icant discussion regarding the inclusion of estrogen
receptorenegative patients based on recently published
data; however, these data are consistent with multiple other
series in patients treated with mastectomy or BCT with
WBI that have found that estrogen receptor negativity is
associated with higher rates of local recurrence (LR). As
such, it was felt that the biology of the tumor rather than
the treatment modality (i.e., limiting RT to the vicinity of
the lumpectomy cavity) is responsible for the higher rates
of LR, and thus, the guideline was made to include estrogen
receptorenegative patients. Finally, this report was re-
viewed and approved by the Board of Directors of the ABS.Results
Prior published guidelines
In an effort to guide clinicians, guidelines or consensus
statements have been previously published by groups,
including the American Society for Radiation Oncology,
Groupe Europeen de Curietherapie-European Society for
Therapeutic Radiology and Oncology, American Society
of Breast Surgeons (ASBS), and aforementioned ABS
guidelines (13e16).
Clinical outcomes
Clinical outcomes by technique are presented in Table 2
(17e64). The top of this table focuses on the published
randomized trials to date; although there is a paucity of
randomized data, multiple randomized Phase III trials are
currently accruing or are recently closed and an increasing
number of prospective, multi-institution, and single institu-
tion retrospective series are being published at this time.
Interstitial APBI represents the techniquewith the longest
followup to date. Multiple series have reported outcomes
with more than 10-year followup to date (22e39). A
randomized trial from Hungary randomized 258 women
with T1N0-1mi, Grades 1e2 nonlobular breast cancer with
negative surgical margins toWBI or partial breast irradiation
(high-dose rate, HDR, accelerated [36.4 Gy/7 fx, 69% of
patients] or electrons standard fractionation to a limited field
[50 Gy/25 fx, 31% of patients]). At 5 years, no difference in
LR was noted (3.4% vs. 4.7%), and rates of excellent/good
cosmesis were significantly improved with HDR-based
APBI compared with electrons (81% vs. 70%) (19). Ten-
year results have recently been presented, and the key find-
ings remain unchanged. Although a few smaller and older
series have published poor outcomes or cosmesis, multiple
more recent and larger series have demonstrated excellentoutcomes including a nonrandomized matched-pair analysis
which found no difference in IBTR, regional recurrence
(RR), or survival between patients undergoing interstitial
APBI or WBI at 12 years (22, 27, 28, 40). The Radiation
Therapy Oncology Group (RTOG) trial 9517 was a Phase
I/II trial of 99 patients undergoing interstitial APBI with
either HDR or low-dose-rate brachytherapy. At 5/10 years,
the rates of IBTR were 4.7%/5.9%, with 3e9% rates of
Grades 3 and 4 toxicity (34).
Balloon-based APBI emerged with the introduction of
the MammoSite applicator (Hologic, Inc, Bedford, MA).
A prospective trial of 70 patients at 5 years showed no
LRs developed, and more than 80% of patients had excel-
lent/good cosmesis. These outcomes have been confirmed
by the larger ASBS Cancer MammoSite Registry Trial of
1440 women. This study, with 54-month followup, found
the 5-year actuarial rate of IBTR to be 3.8% with 90.6%
of patients reporting excellent/good cosmesis at 60 months
(49, 50). A retrospective multi-institutional analysis of
nearly 500 patients with 24-month followup demonstrated
a 1.2% IBTR with more than 90% of patients having excel-
lent/good cosmesis (48). Although there are no published
randomized comparisons of balloon APBI with WBI,
a retrospective matched-pair analysis comparing outcomes
from the ASBS Registry with those of WBI patients from
the SEER database found no difference in rates of RR or
survival at 5 years (65).
External beam RT has also been developed as a method
to deliver APBI. Two older randomized trials from the
United Kingdom found increased rates of LR with partial
breast techniques that are inconsistent with today’s standard
techniques (17, 18). A more recent prospective trial from
Italy found reduced rates of acute toxicities with
intensity-modulated RTebased APBI (21). RTOG 0319
was a Phase I/II trial of 52 patients undergoing external
beam RT APBI and found the 4-year rate of IBTR to 6%,
with only 4% of patients developing Grade 3 toxicity.
Although two recent series have documented increased
rates of toxicity and poor cosmesis, an interim analysis of
the National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-39/RTOG 0413 trial evaluating the 1386
patients receiving three-dimensional conformal radio-
therapy APBI found no significant toxicity issues at 41
months with a 3% rate of Grade 3 or more fibrosis (52,
53, 66). On the contrary, recent analysis of the Randomized
Trial of Accelerated Partial Breast Irradiation Trial
comparing external beam APBI and WBI found that this
form of APBI was associated with an increased rate of
adverse cosmesis and Grade ½ toxicities with short-term
followup (67).
Intraoperative therapy, although included in Table 2 as
a partial breast technique, should not be grouped with other
APBI modalities in terms of outcomes, toxicities, and
guidelines recommendations because of significant differ-
ences in the technique. Although initial outcomes from
a randomized noninferiority trial comparing intraoperative
Table 2
Series evaluating clinical outcomes by partial breast technique
Trial Year published
Number of
patients APBI technique Followup (mo) Findings
Randomized
Christie Hospital (17) 1993 708 EBRT 65 LR 15% limited field vs. 11% WBI and increased LR with ILC and limited field
United Kingdom (18) 2005 174 EBRT Trend toward increased LR with APBI (12% vs. 4%)
Hungary (19) 2007 258 Interstitial/electron 66 No difference in LR (4.7% vs. 3.4%) and HDR associated with improved cosmesis
TARGIT (20) 2010 2232 Intraoperative No difference in LR between intraoperative therapy and WBI; recent update
demonstrates increase in IBTR for IORT cohort
Florence (21) 2010 259 EBRT (IMRT) Grade ½ skin toxicity 41% WBI vs. 5.8% APBI
Nonrandomized
Guy’s Hospital (22) 1996 27 Interstitial (HDR) 72 37% IBTR at 8 y
Oschner Clinic (23) 2000 50 Interstitial (HDR) 75 No difference in outcomes and toxicities between APBI and EBRT cohort
University of Kansas (24) 2001 24 Interstitial (HDR) 47 0% IBTR at 4 y
Virginia Commonwealth (25) 2003 44 Interstitial (HDR/LDR) 42 0% LR at 4 y, 80% excellent/good cosmesis, and 90% with HDR
Ontario (26) 2003 39 Interstitial (HDR) 91 5-y IBTR 16.2% and 5% in-field
Guys’ Hospital (27) 2004 50 Interstitial (HDR-Cs) 75 18% IBTR, 7/9 IBTR in-field, and 80% excellent/good
Hungary (28) 2004 70 Interstitial (60Co) 144 27/34 Disease free and 50% poor cosmesis
Czech Republic (29) 2005 25 Interstitial (HDR) 11 0% IBTR at 1 y
Australia (30) 2006 7 Interstitial (HDR) 43 No LR
Tufts University (31) 2007 32 Interstitial (HDR) 70.5 5-y IBTR 6.1% and beyond 5 y 90% excellent cosmesis
University of Wisconsin (32) 2008 273 247-Interstitial (HDR),
26 MammoSite
48.5 5-y LR 2.2% low risk vs. 6.4% high risk (!50 y, ER, and LNþ)
Spain (33) 2008 26 Interstitial (HDR) 53 6-y LR 0% and 87.5% excellent/good cosmesis
RTOG 9517 (34) 2008 99 Interstitial (HDR/LDR) 73 5-y IBTR 3% (HDR) and 6% (LDR)
3%/9% Grade 3/4 toxicity with HDR/LDR
Sweden (35) 2009 50 Interstitial (PDR) 86 7-y LR 4% and 56% excellent/good cosmesis
Japan (36) 2009 45 Interstitial (HDR) 4% LR
Hungary (37) 2010 45 Interstitial (HDR) 133 12-y IBTR 9.3% and 78% excellent/good cosmesis
MGH (38) 2011 50 Interstitial (LDR) 134 12-y LR 15%
GermaneAustrian (39) 2011 274 Interstitial (HDR/PDR) 63 5-y LR 2% and 90% excellent/good cosmesis
William Beaumont (40) 2011 199 Interstitial (HDR) 126 No difference in LR between APBI (5.0%) and WBI (3.8%) at 12 y
St. Vincent (41) 2004 32 Balloon 11 86% Excellent/good cosmesis and 25% acute erythema/desquamation
Rush (42) 2004 112 Balloon !1 y Well tolerated and 4/112 punctured or ruptured balloon
Kaiser Permanente (43) 2006 51 Balloon 16 0% LR and 95.6% excellent/good cosmesis
Multi-Institution (44) 2006 44 Balloon 14 82% Skin discoloration/inflammation and 18% telangiectasias
Germany (45) 2006 32 Balloon 20 26% Telangiectasias, 56% hyperpigmentation, and 91% erythema
MammoSite Initial Trial (46) 2007 70 Balloon 5-y LR 0% and 83.3% excellent/good cosmesis
William Beaumont (47) 2007 80 Balloon 22 3-y IBTR 2.9%, 88.2% excellent/good cosmesis, and decreased cosmesis with
!7 mm spacing
Multi-Institution (48) 2008 483 Balloon 24 1.2% IBTR and 91% excellent/good cosmesis
ASBS Registry (49, 50) 2011 1440 Balloon 54 5-y IBTR 2.6%, 5.4%, and 5.3% by risk group and 90.4% excellent/good cosmesis
Rocky Mountain (51) 2007 55 EBRT (IMRT) 10 0% LR and 54/64 excellent/good cosmesis
Tufts University (52) 2009 60 EBRT 15 10% Moderate/severe late toxicity, 25% Grades 2e4 fibrosis, and 81.7%
excellent/good cosmesis
University of Michigan (53) 2010 34 EBRT (IMRT) 24 7/32 Unacceptable cosmesis
RTOG 0319 (54) 2010 52 EBRT 54 4-y IBTR 6% and 4% Grade 3 toxicity
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271C. Shah et al. / Brachytherapy 12 (2013) 267e277radiation therapy (IORT) with WBI found no difference in
outcomes at 4 years, a more recent update suggested a 2%
higher rate of IBTR compared with WBI, whereas updates
from the Milan trial have found higher than the expected
rates of IBTR (20, 68, 69).
Patient evaluation
Patient evaluation for APBI should be a multi-
disciplinary approach that incorporates the breast surgeon,
radiation oncologist, and medical oncologist. Ideally, the
patient should be evaluated by a radiation oncologist before
or within a few days of surgery. A detailed history should
be performed to rule out absolute/relative contraindications
for BCT in general or APBI including pregnancy, prior RT
to the breast or chest, connective tissue disease, or strong
family history (potentially requiring genetic testing). Breast
examination should be performed to help guide clinicians
as to whether a patient will be a good candidate for APBI.
Mammograms should be reviewed and evaluated for
multifocality or multicentricity and diffuse calcifications.
Pathology reports from the biopsy and excision should be
reviewed to assess tumor size, histology, grade, receptor
status, margin status, presence of LVSI, presence of exten-
sive intraductal component (EIC), and nodal status as all
these factors can help to guide clinicians in recommending
appropriate adjuvant therapy for their patients. Patients
with calcifications associated with their disease should have
a postoperative mammogram (70).
Patient selection
The following section provides a review of the literature
used to guide patient selection criteria. Based on these
studies and the consensus of the panel, the ABS acceptable
criteria are presented in Table 3 .
Histology
To date, most randomized and prospective trials limited
patient inclusion to ductal histologies with limited numbers
of patients with lobular carcinoma (ILC) or DCIS treated
on the initial studies.
With regard to lobular histology, these patients were
excluded from the randomized Hungarian and intraoperativeTable 3
American Brachytherapy Society acceptable criteria for accelerated partial
breast irradiation
Criteria
Age $50 y old
Size #3 cm
Histology All invasive subtypes and DCIS
Estrogen receptor Positive/negative
Surgical margins Negative
Lymphovascular space invasion Not present
Nodal status Negative
DCIS 5 ductal carcinoma in situ.
272 C. Shah et al. / Brachytherapy 12 (2013) 267e277radiotherapy trials but included in the Christie Hospital
trial. This randomized trial which used electrons to deliver
APBI found that in patients with ILC, APBI was associated
with increased rates of LR (42% vs. 17%) and was confirmed
by a smaller Swedish study (17, 35). However, the data
from the Christie trial are difficult to interpret in light of
the outdated technique for target delineation, a treatment
delivery technique that is no longer routinely used, and a lack
of modern image guidance during treatment delivery.
However, the more recent GermaneAustrian trial found no
difference rates of LR between ILC and invasive duct carci-
noma (IDC) patients (39). The largest reported series comes
from William Beaumont Hospital (WBH), which evaluated
16 ILC patients and found no difference in LR compared
with IDC patients (0% vs. 2.5%) (71).
DCIS remains a controversial topic because of limited
data and its exclusion from the initial APBI trials. However,
recent data from the ASBS MammoSite Registry Trial eval-
uated the 194 patients with DCIS treated and found a 5-year
LR rate of only 3.4% (72). Also, data from WBH and Bryn
Mawr Hospital have confirmed excellent results albeit with
small numbers of patients (73, 74). A recent pooled analysis
of 300 DCIS patients treated with APBI found a 5-year
IBTR rate of 2.6%; furthermore, this analysis identified no
difference in IBTR between DCIS patients and suitable risk
invasive patients (75). ABS Guideline: All invasive subtypes
and DCIS are acceptable.
Discussion. Previous ABS guidelines and other recommen-
dations and trials have limited recommendations to only
IDC. However, over the past several years, there have been
a significant number of publications that allow for a change
in the guideline. With regard to DCIS, more than five publi-
cations have now documented the efficacy of APBI in
patients with DCIS including a pooled analysis of 300
patients. In light of these findings, DCIS has been included
in acceptable histologies. Implicit in this recommendation
is the acknowledgment that further data from phase III
trials will be needed to conclusively establish the efficacy
of APBI in patients with pure DCIS. Nonetheless, with
no recent data documenting an increased risk of IBTR in
these patients when treated with APBI, the panel felt that
the inclusion of DCIS was appropriate.
With regard to lobular histology, there remains a paucity
of data specifically addressing the use of APBI in patients
with this invasive carcinoma subtype. However, over the
past few years, two small series have been published ad-
dressing the role of APBI in these patients (no series larger
than 50 patients). Because no modern series have been
published documenting higher rates of IBTR for ILCs
and multiple series using WBI have found comparable
outcomes between IDCs and ILCs, it was the consensus
opinion that lobular carcinomas should be considered
acceptable for treatment (76e79). Again, implicit in this
recommendation is the acknowledgment that further data
from Phase III trials (and other prospective data) will beneeded to conclusively establish the efficacy of APBI in
patients with ILC.
Nodal status
To date, limited data remain available on patients with
node-positive disease treated with APBI despite node-
positive patients being included in the Yorkshire Breast
Cancer Group Trial, RTOG 9517, RTOG 0319, Oschner
Clinic experience, University of Wisconsin experience,
Kaiser Permanent experience, and intraoperative radio-
therapy trial. Data from older series have confirmed
that without axillary lymph node sampling, increased rates
of locoregional recurrence can be expected in patients under-
going APBI (17, 18). Furthermore, a series of three patients
from Tufts University found that two of three patients that
were node positive treatedwithAPBI subsequently developed
an IBTR (31). A retrospective review of 39 node-positive
patients treated with APBI at WBH found no difference in
IBTR at 5 years compared with node-negative patients with
increased rates of RR and distant metastases (DM) in node-
positive patients (80). Also, data from the high-risk series
from the University of Wisconsin that included node-
positive patients found no difference in outcomes compared
with a low-risk cohort (32). ABS Guideline: Off-protocol,
patients should be node negative.
Discussion. At this time, there remains insufficient evidence
to support treatment of node-positive patients with APBI
(even with limited nodal involvement). Older series have
identified higher rates of failure and the largest modern
series consists of only 39 patients. Furthermore, in light of
the recently reported randomized Phase III trial (MA.20)
demonstrating improvements in disease-free survival with
the addition of regional irradiation to whole-breast treat-
ment, node-positive patients should not be offered APBI
off-protocol (81). Although currently accruing trials have
included patients with limited nodal disease, it will be
several years before mature data are available.
Tumor size
Although tumor size has been used in the past to risk
stratify BCT patients, recent data suggest that it may not
be associated with IBTR in patients undergoing APBI
(82, 83). An analysis of more than 1800 patients treated
with BCT and WBI found pathologic tumor size to be asso-
ciated with IBTR and DM; however, a recent pooled anal-
ysis of outcomes from the ASBS Registry and WBH did
not find tumor size to be associated with IBTR, with nearly
2000 patients evaluated (83). ABS Guideline: Tumor size
should be less than or equal to 3 cm (including pure DCIS).
Discussion. To date, limited research has been performed
to determine the ideal tumor size criteria for patients under-
going APBI. As noted previously, because of paucity of
data available, limited conclusions can be drawn. Further-
more, because of selection bias, published studies are of
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tumors. Based on these findings, and consistent with previ-
ously published consensus criteria and guidelines along
with clinical trial inclusion criteria, the guideline remains
3 cm. In addition, the panel does not believe that APBI
should be applied off-protocol in the neoadjuvant setting.
Age
Previous randomized trials of women undergoing BCT
have documented increased rates of IBTR with younger
women (8). An analysis of the Christie Hospital random-
ized trial with partial breast irradiation did not find age to
be associated with breast recurrence on multivariate anal-
ysis (84). However, the pooled analysis previously dis-
cussed found a trend for increased rates of IBTR for
patients under 50 years old (83). ABS Guideline: Patients
should be 50 years or older.
Discussion. To date, limited research has been completed
to determine the ideal age criteria for patients undergoing
APBI. As noted previously, because of paucity of data
available, limited conclusions can be drawn but in light
of the pooled analysis finding a trend for increased rates
of IBTR in patients under age 50 years and similar data
seen in patients undergoing WBI, the guideline has been
left at 50 years old. The panel did not believe that there
were sufficient data to specifically exclude younger patients
from being treated with APBI but felt that caution was still
warranted. Nonetheless, implicit in this recommendation is
the acknowledgment by the panel that further data from
Phase III trials will be needed to conclusively establish
the efficacy of APBI in younger patients. Although no
recent data documenting an increased risk of IBTR in these
patients when treated with APBI (beyond that seen when
WBI is used) have been conclusively identified, the panel
felt that the inclusion of women less than age 50 years
was not appropriate at this time.
Receptor status
Increasing data have suggested that estrogen receptor
negativity is associated with IBTR in women undergoing
APBI. As previously mentioned, a pooled analysis of the
ASBS registry and data from WBH found that the only
factor associated with IBTR was estrogen receptor nega-
tivity (83). Also, a review of 106 patients with cautionary
features (including estrogen receptor negativity) found that
receptor negativity was associated with a higher rate of
IBTR (11.8% vs. 2.2%) (74). An analysis of high-risk
patients including estrogen receptorenegative patients
from the University of California Irvine also found that
estrogen receptor negativity was associated with a decrease
in recurrence-free survival (85). This has also been noted in
older women who traditionally have excellent outcomes;
analysis of the 537 women from the ASBS registry over
age 70 years found that estrogen receptorenegative patients
had higher rates of LR and decreased survival comparedwith estrogen receptorepositive patients (86). ABS Guide-
line: Estrogen receptor may be positive or negative.
Discussion. As noted previously, there are increasing
numbers of small series identifying higher rates of IBTR
in estrogen receptorenegative patients undergoing APBI
compared with estrogen receptorepositive patients under-
going APBI. Although these studies suggest that estrogen
receptor negativity is associated with higher rates of local
failure, similar findings have been seen with WBI and
mastectomy and therefore may be indicative of the biology
of an estrogen receptorenegative tumor and not the treat-
ment modality (87e89). To date, there are no data
comparing local outcomes in estrogen receptorenegative
patients receiving mastectomy, WBI, and APBI, and there-
fore, no data to suggest that rates of IBTR are higher in
estrogen receptorenegative patients receiving APBI
compared with those who receive WBI.Margins
Although margin status has been associated with IBTR
in patients undergoing WBI after BCS, limited data are
available for patients undergoing APBI (90). A recent anal-
ysis of the MammoSite Registry found that close and posi-
tive margins were associated with a trend for increased
rates of IBTR (83). Furthermore, a series of 48 patients
prospectively treated with multicatheter brachytherapy
from Korea did find that recurrence was associated with
patients with close surgical margins (!2 mm) (91). ABS
Guideline: Surgical margins should be negative.
Discussion. Although limited, the evidence presented to
date suggests that close/positive margins are associated
with higher rates of IBTR in patients undergoing APBI.
These findings are consistent with large studies of patients
undergoing WBI, and as such, the guideline remains consis-
tent with previous consensus statements and guidelines
recommending negative surgical margins. Because of
differences in pathologic assessment of surgical margins,
a lack of consistent data identifying that a certain ‘‘ideal’’
margin exits, and the fact that NSABP continues to use
a definition of ‘‘no tumor on ink,’’ the panel finds that the
guideline should remain a negative margin.Other
Factors often associated with IBTR include LVSI and
multifocality. However, limited data exist examining these
factors in APBI patients. A review of 106 cautionary risk
patients did not find focal LVSI to be associated with IBTR,
RR, or DM (74). Recent data from WBH evaluated patients
with and without LVSI and found that LVSI was associated
with increased rates of RR and DM and a decrement in
disease-free survival with no impact on IBTR or survival
(92). The same series evaluated the impact of EIC and mul-
tifocality and found no difference in rates of IBTR based on
274 C. Shah et al. / Brachytherapy 12 (2013) 267e277either factor; however, EIC was associated with higher rates
of RR (92).
With regard to tumor grade, the Early Breast Cancer
Trialists Collaborative Group meta-analysis has found that
in women undergoing BCT, tumor grade was associated
with recurrence risk at 10 years; also, the European Orga-
nisation for Research and Treatment of Cancer (EORTC)
boost trial found tumor grade to be one of the most impor-
tant factors associated with LR (9, 93). With regard to
APBI, the Christie Hospital trial initially suggested that
grade was associated with higher rates of breast recurrence
(84). More recently, data from the ASBS registry found
increasing grade to be associated with higher rates of RR
(94). ABS Guideline: LVSI should not be present (because
of differences in pathologic assessment for LVSI, the pres-
ence of LVSI [focal or diffuse] is a contraindication).
Discussion. LVSI has been found to be associated with
IBTR in patients undergoing WBI; although small series
evaluating the impact of LVSI in patients undergoing APBI
have not found that LVSI impacts IBTR, only two reports
have been published to date. Therefore, it is the consensus
opinion that LVSI not be present. With regard to other
factors including tumor grade and multifocality, limited
data are available regarding these factors in patients treated
with APBI and similarly when examining the literature on
these features in patients undergoing WBI, controversy
continues to exist; as such, they were not included in the
guideline. With respect to EIC, data extrapolated from
WBI series have confirmed that in negative surgical margin
cases, that EIC is not a factor associated with IBTR (95).
As such, EIC was not included in the consensus guidelines
at this time as the panel believes that it is not a factor that
should be used to stratify patient in light of negative
surgical margins.Technical guidelines
Previous guidelines have been published with regard to
dosimetric guidelines. Previously published guidelines had
focused on target coverage ($90% dose received by
$90% target volume, V150 !70 cm
3 [interstitial]/50 cm3
[balloon], V200 !20 cm
3 [interstitial]/10 cm3 [balloon],
and dose homogeneity index$0.75) and skin doseevolume
histogram parameters (maximum #100% [interstitial],
!145% [balloon] consistent with the constraints of the
NSABP B-39 protocol) (13, 14). With the development of
multilumen balloon catheters and novel external beam
techniques including intensity-modulated RT and protons,
dosimetric guidelines should be revised to reflect the
improvements in target coverage and normal tissue
constraints possible with these new techniques. Before
treatment, all patients should undergo CT-based planning.
Based on clinical experience, expansions of 1e2 cm should
be used to expand the seroma cavity to an appropriate
planning target volume. Target margins may beindividualized based on treatment technique and pathologic
features (e.g., surgical margin status). Prescriptions have
varied in the literature, but the most common prescriptions
used are 34 Gy in 10 fractions twice daily for interstitial
and intracavitary treatment and 38.5 Gy in 10 fractions twice
daily for external beamebased treatment. A comprehensive
review of each technique and the corresponding formal dosi-
metric recommendations are beyond of the scope of this
review, but for reference, the NSABP B-39 guidelines and
those presented by Wazer et al. may be used (14, 96).
It should also be noted that although the focus of these
guidelines is APBI as a sole modality of treatment, that
in appropriately selected cases, brachytherapy remains an
excellent modality for boost following WBI as well. Bra-
chytherapy for boost treatment is a well-documented and
efficacious modality of treatment having been used in the
EORTC randomized trial comparing mastectomy and
BCT and the EORTC boost trial (2, 93). Furthermore,
studies have demonstrated excellent long-term clinical
outcomes with respect to tumor control and toxicities with
multiple forms of brachytherapy boost; a recently published
Phase II trial with 10-year followup had a 96% local control
rate with 93% of patients having excellent/good cosmesis
(97e99). Although brachytherapy boost has documented
excellent clinical, toxicity, and cosmetic results with inter-
stitial HDR and low-dose-rate brachytherapy, because of
the technical challenges of performing interstitial brachy-
therapy, noninvasive image-guided breast brachytherapy
(NIBB) has been developed recently. This technique, which
consists of breast immobilization and mild compression,
mammography-guided target delineation using 192Ir bra-
chytherapy with specialized surface applicators, results in
highly collimated photon emissions. A dosimetric study
from Tufts University found improved dosimetric outcomes
including lower skin V100/D90/D50 and reduced chest wall/
lung dose using NIBB compared with electrons or three-
dimensional conformal radiotherapy; these findings were
confirmed by a multi-institutional registry study which
documented no acute or late Grade 3 toxicities and 100%
excellent/good cosmesis in a series of 146 patients (100,
101). This has led to the activation of a multi-institutional
study to evaluate NIBB for APBI (102). Although future
studies are required to further evaluate NIBB, the role of
brachytherapy as a boost technique has sufficient data
available to support its continued use.Conclusions
These guidelines have been updated to provide clini-
cians with appropriate patient selection criteria to allow
APBI to be used in a manner that will optimize clinical
outcomes and patient satisfaction. The panel recommends
that the application of APBI in any of these settings should
still be approached carefully (on a case-by-case basis) with
the understanding that until mature Phase III trial results are
275C. Shah et al. / Brachytherapy 12 (2013) 267e277available, patients and clinicians need to be cognizant of
the limited long-term data establishing the efficacy of this
treatment approach.
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